Drug Trial Radar · NCT04685564
A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016
Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Feb 5, 2021
Primary completion
Sep 8, 2021
Study completion Nov 2, 2021
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single dose-escalation phase Ⅰa clinical study to observe the safety and pharmacokinetic profiles of RBD1016 in healthy subjects. The study consists of screening period (Day -28 to Day -1), treatment period (Day 1 to Day 2), safety assessment period (to Day 29) and safety follow-up period (up to Day 85).
Conditions
- Healthy Volunteers
Interventions
RBD1016Drug
"Sentinel cohort" design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission. Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission.
PlaceboDrug
the same as RBD1016
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety assessment, AE and SAE of ascending single dose of RBD1016 in healthy subjects.Time frame: up to Day 29
- To evaluate the safety assessment, 12-lead ECG of ascending single dose of RBD1016 in healthy subjects.Time frame: up to Day 29
- To evaluate the safety assessment, vital signs of ascending single dose of RBD1016 in healthy subjects.Time frame: up to Day 29
- To evaluate the safety assessment, physical examinations of ascending single dose of RBD1016 in healthy subjects.Time frame: up to Day 29
- To evaluate the safety assessment, clinical lab examinations of ascending single dose of RBD1016 in healthy subjects.Time frame: up to Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Randwick, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.